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Patient And Renal Outcomes Of Posttransplant Lymphoproliferative Disorder Following Solid
Organ Transplantations - A Single Center Experience
Kashka Mallari, Goni Katz-Greenberg*, Maria Martinez-Cantarin*

Introduction: Post-transplant Proliferative Disorder (PTLD) is a significant complication after
solid organ transplantation (SOT). Major risk factors that contribute to the development of PTLD
include Epstein-Barr Virus (EBV) infection and degree of immunosuppression. Despite novel
therapies, the 5-year survival rate of PTLD only improved from 40% to 50% over the years. The
reported 5-year survival rate of PTLD also remains significantly lower compared to around 90%
in other malignancies such as breast and colon cancer. In our center, we hypothesize better
transplant outcomes compared to those reported in preceding literatures.

Methods: We retrospectively reviewed the electronic medical records of all patients who had a
SOT followed by the diagnosis of PTLD from the last 10 years. We collected donor and recipient
characteristics, time interval between SOT and PTLD diagnosis, disease characteristics based on
the WHO 2017 classification, response to treatment, and outcomes. We calculated the mortality
rate and graft failure rate to evaluate patient survival and allograft survival outcomes.

Results: In our center, there were 32 patients that underwent a SOT and were later diagnosed
with PTLD. Of them, 12 were female, and 8 were non-Hispanic blacks. PTLD was diagnosed in
18 kidney transplants, 11 liver transplants, 2 simultaneous kidney-pancreas transplants, and one
simultaneous liver-kidney transplant. Mean time from SOT to PTLD diagnosis was 63 months,
with 13 patients diagnosed in the 1st year post transplant. The main PTLD subtype was

monomorphic B-cell lymphoma (20/32 patients) and 16 of them were diffuse large B cell
lymphomas (DLBCL). Three patients had graft involvement by PTLD. Mean serum creatinine
was 2.29 mg/dL, with mean follow up time of 57.7 months. There were 11 deaths in the cohort
(33%), and 5 graft failures (15%) at the five year follow up mark.

Discussion: Patient survival and allograft survival in PTLD patients are better in our center than
reported in the literature. In our cohort, PTLD was not a significant cause of graft failure after 5
years of follow up. Further studies are needed to look at the disease characteristics that will help
determine more specific prognostic factors.

